The trial - AFIRE (Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease) is a subgroup analysis was to examine rivaroxaban monotherapy benefits and their relation to the time between stenting and enrollment among patients after coronary stenting.

In total of 2,215 patients with atrial fibrillation and stable coronary artery disease in the AFIRE trial, rivaroxaban monotherapy was noninferior to rivaroxaban plus antiplatelet therapy (combination therapy) in terms of efficacy and superior for safety endpoints. However, thrombotic risk after antiplatelet therapy cessation remained a concern among 1,444 patients who had undergone coronary stenting >1 year before enrollment.

Efficacy and safety endpoints for monotherapy were superior to combination therapy, with HRs of 0.70 for efficacy and 0.55 for safety. For ischemic endpoints, the HR was 0.82. The HR became smaller with longer time between stenting and enrollment.

n patients with atrial fibrillation after coronary stenting, the benefits of rivaroxaban monotherapy for efficacy and safety endpoints were consistent with those in the whole AFIRE trial population. The benefits became apparent with longer time between stenting and enrollment.



Disease Condition ,Therapeutic Modality ,Risk factors-comorbidities,Arrhythmias,Interventional Cardiology,Atherosclerosis and Risk Factors,Atrial Fibrillation,Percutaneous Coronary Intervention,Primary Prevention,Secondary Prevention